| First Author | Schumacher N | Year | 2022 |
| Journal | Biochim Biophys Acta Mol Cell Res | Volume | 1869 |
| Issue | 1 | Pages | 119141 |
| PubMed ID | 34610348 | Mgi Jnum | J:317494 |
| Mgi Id | MGI:6854322 | Doi | 10.1016/j.bbamcr.2021.119141 |
| Citation | Schumacher N, et al. (2022) ADAM17 orchestrates Interleukin-6, TNFalpha and EGF-R signaling in inflammation and cancer. Biochim Biophys Acta Mol Cell Res 1869(1):119141 |
| abstractText | It was realized in the 1990s that some membrane proteins such as TNFalpha, both TNF receptors, ligands of the EGF-R and the Interleukin-6 receptor are proteolytically cleaved and are shed from the cell membrane as soluble proteins. The major responsible protease is a metalloprotease named ADAM17. So far, close to 100 substrates, including cytokines, cytokine receptors, chemokines and adhesion molecules of ADAM17 are known. Therefore, ADAM17 orchestrates many different signaling pathways and is a central signaling hub in inflammation and carcinogenesis. ADAM17 plays an important role in the biology of Interleukin-6 (IL-6) since the generation of the soluble Interleukin-6 receptor (sIL-6R) is needed for trans-signaling, which has been identified as the pro-inflammatory activity of this cytokine. In contrast, Interleukin-6 signaling via the membrane-bound Interleukin-6 receptor is mostly regenerative and protective. Probably due to its broad substrate spectrum, ADAM17 is essential for life and most of the few human individuals identified with ADAM17 gene defects died at young age. Although the potential of ADAM17 as a therapeutic target has been recognized, specific blockade of ADAM17 is not trivial since the metalloprotease domain of ADAM17 shares high structural homology with other proteases, in particular matrix metalloproteases. Here, the critical functions of ADAM17 in IL-6, TNFalpha and EGF-R pathways and strategies of therapeutic interventions are discussed. |
